YUANLIN LIU^1,3, YAN LIU², YAN WANG², QIANG WANG², YAN YAN¹, DANDAN ZHANG^2,*, HUIQIN LIU^2,*

Oncology Research, Vol.33, No.6, pp. 1505-1505, 2025, DOI:10.32604/or.2024.056768 - 29 May 2025

Abstract This article has no abstract. More >

LIBO LIANG¹, XINYI WANG^2,3,4, YUPING ZENG^2,3,4, HAO CHEN^2,3,4, WEN ZHOU¹, HONGYING MU^2,3,4, GA LIAO^5,6,*

Oncology Research, Vol.33, No.6, pp. 1405-1421, 2025, DOI:10.32604/or.2024.056708 - 29 May 2025

Abstract Objectives: Exosomal long noncoding RNAs (lncRNAs) might facilitate epithelial–mesenchymal transition (EMT) in liver cancer after transarterial chemoembolization (TACE), thereby enhancing tumor cell invasiveness and migration. This study investigated the prognostic role of plasma exosomal long noncoding RNA-plasmacytoma variant translocation 1 (lncRNA-PVT1) in TACE treated hepatocellular carcinoma (HCC). Methods: Plasma exosomal lncRNA-PVT1 was evaluated via qPCR before and after TACE. Hepatoma cell behavior was investigated in different HCC cell lines. A lncRNA-PVT1 plasmid was synthesized and overexpressed, and si-lncRNA PVT1 was transfected into poorly invasive cells to reveal its influence on cell characteristics. The lncRNA-PVT1–FoxM1 interaction… More > Graphic Abstract

Dang Hung Tran, Van Tinh Nguyen^*

CMC-Computers, Materials & Continua, Vol.83, No.3, pp. 4679-4698, 2025, DOI:10.32604/cmc.2025.063228 - 19 May 2025

Abstract It is known that long non-coding RNAs (lncRNAs) play vital roles in biological processes and contribute to the progression, development, and treatment of various diseases. Obviously, understanding associations between diseases and lncRNAs significantly enhances our ability to interpret disease mechanisms. Nevertheless, the process of determining lncRNA-disease associations is costly, labor-intensive, and time-consuming. Hence, it is expected to foster computational strategies to uncover lncRNA-disease relationships for further verification to save time and resources. In this study, a collaborative filtering and graph attention network-based LncRNA-Disease Association (CFGANLDA) method was nominated to expose potential lncRNA-disease associations. First, it… More >

Oncology Research Editorial Office

Oncology Research, Vol.33, No.5, pp. 1251-1252, 2025, DOI:10.32604/or.2025.065346 - 18 April 2025

Abstract This article has no abstract. More >

JINGDAN QUAN¹, ZIXIN WAN¹, WEI WU², XINYUAN CAO², JIAYUAN QIU², XIAOYE LIU², ZHIWEI ZHANG^1,*

Oncology Research, Vol.33, No.5, pp. 1069-1089, 2025, DOI:10.32604/or.2025.063005 - 18 April 2025

Abstract One of the most prevalent malignant tumors worldwide, stomach cancer still has a high incidence and fatality rate in China, and the number of young people developing early-onset gastric cancer is steadily increasing. The 5-year survival rate of stomach cancer is typically 30%–35%, the prognosis is bad, the patients’ quality of life is low, and the progression of advanced gastric cancer cannot be effectively managed despite the use of surgical surgery, chemotherapy, and other medicines. We urgently need molecular biomarkers with high specificity and sensitivity to increase the early gastric cancer detection rate, extend patient… More >

HENG ZHANG^1,#, XIAO YANG^2,#, YUJIN GUO³, HAIBO ZHAO⁴, PEI JIANG^5,*, QING-QING YU^3,*

Oncology Research, Vol.33, No.4, pp. 837-849, 2025, DOI:10.32604/or.2024.053882 - 19 March 2025

Abstract As living conditions improve and diagnostic capabilities advance, the incidence of tumors has increased, with cancer becoming a leading cause of death worldwide. Surgery, chemotherapy, and radiotherapy are the most common treatments. Despite advances in treatment options, chemotherapy remains a routine first-line treatment for most tumors. Due to the continuous and extensive use of chemotherapy drugs, tumor resistance often develops, becoming a significant cause of treatment failure and poor prognosis. Recent research has increasingly focused on how long stranded non-coding RNAs (LncRNAs) influence the development of malignant tumors and drug resistance by regulating gene expression More >

RAHUL KUMAR SINGH^1,#, SUROJIT MANDAL^1,#, ADRIJA MOHANTA¹, RITU YADAV¹, RAJIV RANJAN KUMAR¹, RINKU KHATKAR¹, VIVEK UTTAM¹, UTTAM SHARMA¹, MANJIT KAUR RANA², MANJU JAIN³, HARDEEP SINGH TULI⁴, AKLANK JAIN^1,*

Oncology Research, Vol.33, No.3, pp. 591-604, 2025, DOI:10.32604/or.2024.050548 - 28 February 2025

Abstract Objectives: Recently, we and others have demonstrated the involvement of Zinc Finger Antisense 1 (ZFAS1) in cancer development. However, the intricate interplay of ZFAS1 with miRNAs and mRNAs remains to be fully understood. Materials and methods: We followed PRISMA guidelines to retrieve and assess the available literature on the topic “ZFAS1/miRNA/mRNA axis” and “Cancer” from databases such as PubMed, Google Scholar, and ScienceDirect. We also used bioinformatic webtools for analyzing the potential miRNA targets of ZFAS1 and its role in survival of cancer patients along with their role in various biological functions and pathways. Results: Our literature search… More >

ZHOUYANG CHENG^1,#, YUCHEN HUA^2,#, YANG CAO³, JUN QIN^1,*

Oncology Research, Vol.33, No.1, pp. 185-198, 2025, DOI:10.32604/or.2024.042281 - 20 December 2024

Abstract Objective: Gastric cancer (GC) is a globally common cancer characterized by high incidence and mortality worldwide. Advances in the molecular understanding of GC provide promising targets for GC diagnosis and therapy. Long non-coding RNAs (lncRNAs) and their downstream regulators are regarded to be implicated in the progression of multiple types of malignancies. Studies have shown that the lncRNA small nucleolar RNA host gene 4 (SNHG4) serves as a tumor promoter in various malignancies, while its function in GC has yet to be characterized. Therefore, our study aimed to explore the role and underlying mechanism of… More >

CHAOQUN WANG¹, TING ZHANG², CHAOHE ZHANG^3,*

Oncology Research, Vol.32, No.12, pp. 1867-1879, 2024, DOI:10.32604/or.2024.044547 - 13 November 2024

Abstract Background: Drug resistance is the main factor contributing to cancer recurrence and poor prognosis. Exploration of drug resistance-related mechanisms and effective therapeutic targets are the aim of molecular targeted therapy. In our study, the role of long non-coding RNA (lncRNA) AFAP1-AS1 in gemcitabine resistance and related mechanisms were explored in cervical cancer cells. Methods: Gemcitabine-resistant cervical cancer cell lines HT-3-Gem and SW756-Gem were constructed using the gemcitabine concentration gradient method. The overall survival rates and recurrence-free survival rates were evaluated by Kaplan-Meier analysis. The interaction was verified through a Dual-luciferase reporter gene assay and a… More > Graphic Abstract

Oncology Research Editorial Office

Oncology Research, Vol.32, No.11, pp. 1815-1815, 2024, DOI:10.32604/or.2024.056890 - 16 October 2024

Abstract This article has no abstract. More >